Building for future success: the Syncona Partners model

Cell & Gene Therapy Insights 2020; 6(1), 17–23


Published: 31 January 2020
Martin Murphy

Martin Murphy is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 with The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of five Syncona companies: Achilles, Autolus, Blue Earth, OMass and Quell Therapeutics. Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.